SecBot SecBot
8-K ·Filed Apr 7, 2026

OTLK

Outlook Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed7mo ago SEC0001104659-26-040387
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor outcome of the FDA meeting as it will determine whether the BLA for ONS-5010/LYTENAVA will be approved, which is critical for this small-cap biotech's future revenue potential.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.2500
T+0 close · Apr 7, 2026 · via day close
Latest settled
+468.00%
T+60 · $1.42
Vs SPY
+456.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 8 $0.2500entry
  2. T+1 · 7mo ago −11.20%α −11.78% · $0.2220
  3. T+5 · 7mo ago +9.20%α +5.66% · $0.2730
  4. T+20 · 7mo ago −7.20%α −15.75% · $0.2320
  5. T+60 · 4mo ago +468.00%α +456.58% · $1.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Outlook Therapeutics submitted a formal dispute resolution request to the FDA regarding a Complete Response Letter for its ONS-5010/LYTENAVA biologics license application, and the FDA has accepted the request and granted a meeting with the deciding official. This is a procedural step in the regulatory review process for a drug that was previously not approved.

Key Facts

  • Company submitted a Formal Dispute Resolution Request (FDRR) to the FDA regarding a December 30, 2025 Complete Response Letter (CRL) for ONS-5010/LYTENAVA
  • FDA accepted the FDRR and granted a meeting with the deciding official to be conducted in April 2026
  • The BLA concerns ONS-5010/LYTENAVA for treatment of neovascular age-related macular degeneration
  • Company believes existing clinical data from NORSE TWO and NORSE EIGHT trials support approval

Financial Impact

No immediate financial impact disclosed; outcome of FDA dispute resolution will determine future commercial potential

regulatory approvalproduct development timeline

Risk Factors

  • FDA may uphold its Complete Response Letter and deny approval
  • Further delays or requests for additional clinical data could increase development costs
  • Competitive risks if rival treatments gain market share during approval delay

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-040387
Document: tm2611268d1_ex99-1.htm0001104659-26-040387
Document: 0001104659-26-040387-index-headers.html0001104659-26-040387
Document: 0001104659-26-040387-index.html0001104659-26-040387
Document: 0001104659-26-040387.txt0001104659-26-040387

Track record

37 reports on OTLK

Performance horizon

13 of 23 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 18 of 23 went positive at some point.

Filters
  1. Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
  2. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
  3. Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
  4. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  5. Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  6. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
  7. Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
  8. Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  10. Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026